Coronary Syndrome Clinical Trial
Official title:
The Effect of Rosuvastatin and Olmesartan on the Progression of Coronary Atherosclerotic Disease by Smart Angioplasty Research Team: SMART-ROAD Trial
1. Stains have demonstrated consistent benefits to reduce cardiovascular events in several
primary and secondary prevention trials. The suppression of plaque progression or
regression may be a part of mechanism of clinical benefit. The intravascular ultrasound
studies demonstrated that intensive statin therapy can regress or inhibit the
progression of coronary atherosclerosis.
2. Unregulated renin-angiotensin system is important in the pathogenesis of cardiovascular
disease. Angiotensin receptor antagonists (ARB) have been reported to improve clinical
outcomes in patients with heart failure, left ventricular dysfunction, myocardial
infarction, and high-risk patients. Several small studies showed that ARBs were
effective to inhibit the progression of coronary atherosclerosis by intravascular
ultrasound examination.
3. The combined therapy with statins and ARBs may be additive or synergistic effects on
the atherosclerosis regression as well as to improve endothelial dysfunction and
insulin resistance in addition to lowering cholesterol levels and blood pressure when
compared with either monotherapy in patients.
4. Serial computed tomography angiography (CTA) can be utilized to assess the effect of
treatment on coronary plaque morphology. In addition to the assessment of luminal
stenosis, CTA also allows characterization of plaque morphology.
n/a
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00982176 -
Determinants of Cognitive Impairment After Acute Coronary Syndrome
|
N/A | |
Recruiting |
NCT05600088 -
Intracoronary Cryotherapy Effect on Stabilization of Vulnerable Plaque in Patients With NSTEMI or Unstable Angina
|
N/A | |
Recruiting |
NCT06273033 -
Implementation of Contemporary Coronary CT Angiography in Clinical Practice
|
||
Completed |
NCT03193294 -
CORonary MICrovascular Angina (CorMicA)
|
N/A | |
Recruiting |
NCT05476991 -
Evaluation of Low Dose Colchicine and Ticagrelor in Prevention of Ischemic Stroke in Patients With Stroke Due to Atherosclerosis
|
Phase 3 | |
Completed |
NCT05140317 -
5 Years Follow up of the SAPIEN 3 Valve From the DIRECTAVI Trial
|
||
Recruiting |
NCT06103357 -
Identification of Biomarkers in Subjects With Coronary Syndrome (PLAQUE Study)
|
||
Recruiting |
NCT04325867 -
Integrated Distance Management Strategy for Patients With Cardiovascular Diseases in the Context of COVID-19
|
N/A | |
Not yet recruiting |
NCT05300178 -
Use of Various Configurations of Different Arterial Grafts in Total Arterial Revascularization
|
||
Completed |
NCT00769574 -
Assessment of New Biomarkers in the Management and Triage of Patients With Chest Pain and Suspicion of Non ST Elevation Acute Coronary Syndrome.
|
N/A | |
Completed |
NCT00709709 -
Medical Evaluation of Scanner in Coronary Syndrome
|
N/A | |
Completed |
NCT04881552 -
Incidence, Clinical Characteristics and Prognosis of Patients With ST-segment Elevation Myocardial Infarction (STEMI) and Spontaneous Coronary Reperfusion in the Modern Antithrombotic Strategy Area
|
||
Recruiting |
NCT06058182 -
RNA as Prognostic Biomarkers in Patients With Acute Coronary Syndrome
|
||
Recruiting |
NCT04864457 -
Multi-omics Study of Young Adults Coronary Syndrome Patients
|
||
Completed |
NCT04580017 -
Prognostic Accuracy of the HEART Score in Undifferentiated Chest Pain: A Multicenter Validation Study
|
||
Recruiting |
NCT04206683 -
Cerebral Oxygenation and Burst Suppression
|
||
Completed |
NCT03312179 -
STEMI and Incretins Treatment
|
N/A | |
Active, not recruiting |
NCT04936438 -
Clinical Cohort Study - INTERCATH
|
||
Completed |
NCT03772613 -
The Randomized OPTIMAL-ACT Trial
|
Phase 2 | |
Completed |
NCT04990791 -
WILL lOWer Dose Aspirin be Better With Rivaroxaban in Patients With Chronic Coronary Syndromes?
|
Phase 4 |